WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017017615) NOVEL DUAL DELAYED RELEASE ORAL COMPOSITION OF DEXLANSOPRAZOLE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/017615 International Application No.: PCT/IB2016/054467
Publication Date: 02.02.2017 International Filing Date: 27.07.2016
IPC:
A61K 9/22 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
22
Sustained or differential release type
Applicants: ZIM LABORATORIES LTD.[IN/IN]; Ground Floor, Sadoday Gyan, Nelson Square, Chhindwara Road, Nagpur Maharashtra 440013, IN
Inventors: DAUD, Anwar Siraj; IN
JAMALUDDIN, Shamsuddin; IN
Agent: KHURANA & KHURANA, ADVOCATES & IP ATTORNEYS; E-13, UPSIDC, Site-IV, Behind-Grand Venice Kasna Road, Greater Noida, National Capital Region, Uttar Pradesh 201310, IN
Priority Data:
2851/MUM/201528.07.2015IN
Title (EN) NOVEL DUAL DELAYED RELEASE ORAL COMPOSITION OF DEXLANSOPRAZOLE
(FR) NOUVELLE COMPOSITION ORALE À DOUBLE LIBÉRATION RETARDÉE DE DEXLANSOPRAZOLE
Abstract:
(EN) The present disclosure provides a dual delayed release oral pharmaceutical composition of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof. The disclosed dual delayed release pharmaceutical composition can incorporate two pulsatile release formulations (a) and (b), wherein formulation (a) can include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, and (ii) a p H-dependent release-controlled layer; and formulation (b) can include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, (ii) a p H-independent release-controlled layer, and (iii) a p H-dependent release-controlled layer.
(FR) La présente invention concerne une composition pharmaceutique orale à double libération retardée de dexlansoprazole ou de formes hydratées ou de sels de qualité pharmaceutique de celle-ci. La composition pharmaceutique à double libération retardée selon la présente invention peut comporter deux compositions à libération pulsatile (a) et (b), dans laquelle la composition (a) peut comprendre : (i) une particule noyau comprenant de la dexlansoprazole ou un hydrate ou un sel de qualité pharmaceutique de celle-ci et (ii) une couche à libération contrôlée dépendante du pH ; et la composition (b) peut comprendre : (i) une particule noyau comprenant de la dexlansoprazole ou un hydrate ou un sel de qualité pharmaceutique de celle-ci, (ii) une couche à libération contrôlée indépendante du pH et (iii) une couche à libération contrôlée dépendante du pH.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)